Department of Minimally Invasive Surgery, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Department of Anesthesiology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
Biomed Res Int. 2020 May 10;2020:1598037. doi: 10.1155/2020/1598037. eCollection 2020.
To evaluate the impact of mutation status on clinical outcomes of breast cancer treated with inhibitors.
A comprehensive literature search was conducted in online databases from inception to December 31, 2019. The main characteristics and prognostic data of each eligible study were extracted. The odds ratio (OR) for the overall response rate (ORR) and hazard ratio (HR) for progression-free survival (PFS) were estimated using the fixed-effects Mantel-Haenszel model.
A total of 8 studies involving 2670 patients were included for analysis. Overall, the clinical outcomes of inhibitors were significantly influenced by mutation status in breast cancer. After the treatment of inhibitors, breast cancer patients with mutations presented better ORR (mutated group: OR = 1.98 [95% CI, 1.46 to 2.70]; wild-type group: OR = 1.09 [95% CI, 0.78 to 1.53]) and better PFS (-mutated group: HR = 0.65 [95% CI, 0.55 to 0.76]; wild-type group: HR = 0.87 [95% CI, 0.70 to 1.09]). No publication bias was detected for ORR and PFS in our analysis.
In this meta-analysis, it suggests that the association between clinical outcomes of inhibitors and mutation status is dramatic. mutations were a favorable factor in the clinical outcomes of breast cancer treated with inhibitors.
评估 突变状态对接受 抑制剂治疗的乳腺癌患者临床结局的影响。
系统检索在线数据库，时间从建库至 2019 年 12 月 31 日。提取每项合格研究的主要特征和预后数据。采用固定效应 Mantel-Haenszel 模型估计总缓解率（ORR）和无进展生存期（PFS）的风险比（HR）。
共纳入 8 项研究，总计 2670 例患者。总体而言， 抑制剂的临床结局受乳腺癌 突变状态显著影响。接受 抑制剂治疗后， 突变型乳腺癌患者的 ORR 更好（突变组：OR=1.98[95%CI，1.46 至 2.70]；野生型组：OR=1.09[95%CI，0.78 至 1.53]），PFS 更好（-突变组：HR=0.65[95%CI，0.55 至 0.76]；野生型组：HR=0.87[95%CI，0.70 至 1.09]）。本分析中，ORR 和 PFS 均未检测到发表偏倚。
该荟萃分析提示， 抑制剂临床结局与 突变状态之间的关联显著。 突变是 抑制剂治疗乳腺癌患者临床结局的有利因素。
